International Human Genome Sequencing Consortium

International Human Genome Sequencing Consortium
Name	International Human Genome Sequencing Consortium
Formation	1996
Membership	multinational research institutions

Contents

International Human Genome Sequencing Consortium

The International Human Genome Sequencing Consortium united major institutions to produce a reference sequence of the Human genome. The Consortium coordinated efforts among laboratories in the United States, United Kingdom, Japan, France, Germany, China and Canada to deliver results published alongside participants from the Wellcome Trust, National Institutes of Health, Sanger Centre and other centers. Its work intersected with projects such as the Human Genome Project and fostered collaborations with agencies including the National Human Genome Research Institute, the European Molecular Biology Laboratory and the Genome Canada initiative.

Background and Formation

The Consortium emerged from discussions at meetings involving stakeholders from the Human Genome Project, the Wellcome Trust board, leaders from the White House Office of Science and Technology Policy, and representatives of the Department of Energy and the National Institutes of Health who sought international coordination. Early conferences featured participants from the Sanger Centre, Washington University in St. Louis, Broad Institute, Riken, Genoscope, and the Max Planck Society, and drew attention from science policy figures associated with the Royal Society and the European Commission. The formation reflected precedent in multinational science consortia such as the International Space Station and the CERN collaborations.

Membership included the Wellcome Trust Sanger Institute, the U.S. Department of Energy, the National Human Genome Research Institute, Riken Genomic Sciences Center, Genoscope (French National Sequencing Center), the Max Planck Institute for Molecular Genetics, University of Washington, J. Craig Venter Institute participants, and other academic centers from Australia, China, Germany, Japan, Spain, Sweden, Netherlands and Canada. Governance employed steering committees and working groups comprising principal investigators such as leaders from the Sanger Centre consortium, directors associated with the NIH, chairs from the Wellcome Trust, and representatives from national funding bodies like the Medical Research Council (United Kingdom) and the Japan Science and Technology Agency. Coordination used memoranda of understanding with institutional partners including the Broad Institute and consortium liaison offices modeled after structures in the Human Frontier Science Program.

The Consortium applied capillary electrophoresis-based shotgun sequencing developed at centers such as the Broad Institute and the Sanger Centre, integrating clone-based approaches used at Washington University in St. Louis and the J. Craig Venter Institute with emerging whole-genome shotgun strategies championed by teams linked to the Celera Genomics group. Laboratory techniques incorporated protocols from manufacturers like Applied Biosystems and computational pipelines influenced by algorithms from groups at the University of California, Santa Cruz, the European Bioinformatics Institute, and the National Center for Biotechnology Information. Data management relied upon submissions to public repositories including the GenBank database and annotation collaborations with curators at the Ensembl project and the UCSC Genome Browser consortium.

Major Consortium publications presented a draft sequence of the Human genome and subsequent finished assemblies, with landmark papers coauthored by scientists affiliated with the Wellcome Trust Sanger Institute, the National Human Genome Research Institute, and the University of Washington. The publications detailed gene counts that revised estimates from earlier reports, identified classes of repeats characterized previously in studies from the Max Planck Institute for Evolutionary Anthropology and described sequence features compared against genomes of model organisms such as Mus musculus, Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae. Peer-reviewed articles were published in journals including Nature, Science, and Cell and were accompanied by data releases coordinated with databases such as GenBank and the European Nucleotide Archive.

The Consortium engaged with ethical frameworks proposed by panels including advisors from the National Bioethics Advisory Commission, the Presidential Commission for the Study of Bioethical Issues, and institutional review boards at participant centers such as the Sanger Institute and the Broad Institute. Issues addressed included consent models influenced by cases reviewed in the United Kingdom and the United States, data-sharing policies reflecting principles endorsed by the Wellcome Trust and the National Institutes of Health, and discussions of privacy paralleling debates at the Council of Europe and the World Health Organization. Legal and policy analyses referenced intellectual property debates similar to those involving the United States Patent and Trademark Office and technology transfer practices at institutions such as the University of California.

The Consortium’s reference sequence underpinned downstream initiatives at the 1000 Genomes Project, the Human Variome Project, the ENCODE Project, and biomedical programs at the National Institutes of Health, the Wellcome Trust, and national genomics agencies. Its outcomes accelerated clinical genetics programs at hospitals like Mayo Clinic and research centers such as the Broad Institute and influenced biotechnology firms including Illumina and Thermo Fisher Scientific. The Consortium’s model for open data release informed policies at the European Molecular Biology Laboratory and inspired large-scale efforts such as the International Cancer Genome Consortium and precision medicine initiatives like the All of Us Research Program.

Category:Human genome projects Category:Genomics organizations Category:Scientific consortia